<html>

<head>
<meta name="GENERATOR" content="Microsoft FrontPage 6.0">
<meta name="ProgId" content="FrontPage.Editor.Document">
<meta http-equiv="Content-Type" content="text/html; charset=windows-1252">
<title>DRUG TREATMENT</title>
</head>

<body>

<b><font FACE="Arial" SIZE="4">
<p ALIGN="LEFT">DRUG TREATMENT</p>
</font><font FACE="Arial">
<p ALIGN="LEFT">Acute Management of Psychosis in Primary Care</p>
</font></b><font FACE="Arial" SIZE="3">
<p ALIGN="LEFT">In general, antipsychotics used in schizophrenia and related 
psychoses should be initiated</p>
<p ALIGN="LEFT">in secondary care, or as a result of advice from a psychiatrist. 
If acute sedation is</p>
<p ALIGN="LEFT">necessary in primary care, then diazepam should be used. The 
initiation of an</p>
<p ALIGN="LEFT">antipsychotic prior to referral should be avoided due to the 
possibility of masking</p>
<p ALIGN="LEFT">symptoms, thus making diagnosis difficult.</p>
<p ALIGN="LEFT">Test for possible co-existing medical conditions which may be 
causing symptoms and</p>
<p ALIGN="LEFT">any evidence of substance misuse (U&amp;Es, FBC, LFTs, TFT, urine 
drug screen).</p>
</font><font FACE="Arial"><b>
<p ALIGN="LEFT">Initiation and Monitoring of Antipsychotics in Primary Care</p>
</b></font><font FACE="Arial" SIZE="3">
<p ALIGN="LEFT">In general, antipsychotic treatment will be initiated in 
specialist secondary care by an</p>
<p ALIGN="LEFT">experienced psychiatrist. There will however be some patients 
who choose not to</p>
<p ALIGN="LEFT">engage with the specialist service in secondary care. Initiation 
for these patients may</p>
<p ALIGN="LEFT">be by their GP, and this should be done in consultation with the 
appropriate</p>
<p ALIGN="LEFT">consultant and with the CPA key worker/care manager.</p>
<p ALIGN="LEFT">Patients started on an antipsychotic should be re-assessed by 
the practitioner who</p>
<p ALIGN="LEFT">initiated treatment, or another member of the multidisciplinary 
team, at 2-4 weeks and</p>
<p ALIGN="LEFT">at 6-8 weeks to monitor efficacy and side effects.</p>
</font><font FACE="Arial"><b>
<p ALIGN="LEFT">Doses and Polypharmacy</p>
</b></font><font FACE="Arial" SIZE="3">
<p ALIGN="LEFT">Antipsychotic efficacy may take many weeks to begin, so it is 
important to avoid</p>
<p ALIGN="LEFT">excessive dosing whilst waiting for this onset. If sedation is 
required then short term</p>
<p ALIGN="LEFT">benzodiazepines can be used.</p>
<p ALIGN="LEFT">In general it should be possible to achieve control of psychotic 
symptoms using a</p>
<p ALIGN="LEFT">single antipsychotic drug.</p>
</font><font FACE="Arial"><b>
<p ALIGN="LEFT">Monitoring of Adverse Effects</p>
</b></font><font FACE="Arial" SIZE="3">
<p ALIGN="LEFT">The side effect profile will depend on the type of drug used. 
The relative side effects</p>
<p ALIGN="LEFT">are listed in Appendix 1</font><font FACE="Arial" SIZE="3"><i>.
</i>If adverse effects are suspected during routine clinical</p>
<p ALIGN="LEFT">monitoring appropriate tests should be considered (including BP, 
pulse, U&amp;Es, FBC,</p>
<p ALIGN="LEFT">LFTs, AND serum prolactin as a minimum). ECG and EEG may also be 
helpful.</p>
<p ALIGN="LEFT">All drugs should be stopped if </font>
<font FACE="Arial" SIZE="3"><i><b>neuroleptic malignant syndrome </b></i>is 
suspected (see</p>
<p ALIGN="LEFT">over), or the neutrophil count falls below 1.5.</p>
<p ALIGN="LEFT">Weight gain is often reason for non-compliance and should be 
monitored. There is no</p>
<p ALIGN="LEFT">available accurate data comparing weight gain with different 
antipsychotics, but there</p>
<p ALIGN="LEFT">is a growing view that this is more of a problem with the 
atypicals. Most weight is</p>
<p ALIGN="LEFT">gained during the first 12-16 weeks of therapy, and the 
mechanism is unclear.</p>
<p ALIGN="LEFT">Women seem to be more affected than men (Bazire, S., 
Psychotropic Drug Directory,</p>
<p ALIGN="LEFT">2000).</p>
</font><font FACE="Arial"><b>
<p ALIGN="LEFT">Drug Interactions</p>
</b></font><font FACE="Arial" SIZE="3">
<p ALIGN="LEFT">Smoking may decrease plasma levels of some antipsychotic drugs. 
An increase in</p>
<p ALIGN="LEFT">plasma levels, and associated adverse effects, may occur in 
patients stopping</p>
<p ALIGN="LEFT">smoking.</p>
<p ALIGN="LEFT">Consult the BNF or product SPC for detailed information about 
drug interactions of</p>
<p ALIGN="LEFT">specific drugs.</p>
</font><font FACE="Arial"><b>
<p ALIGN="LEFT">Repeat Prescribing</p>
</b></font><font FACE="Arial" SIZE="3">
<p ALIGN="LEFT">There will be some patients who adhere to their treatment better 
if medication is</p>
<p ALIGN="LEFT">prescribed by their GP. In the interests of promoting good 
adherence the psychiatrist</p>
<p ALIGN="LEFT">may ask the GP to become more involved in the management of the 
patient, and</p>
<p ALIGN="LEFT">undertake routine repeat prescribing within a shared care 
arrangement. In these</p>
<p ALIGN="LEFT">circumstances clear agreement as to who is prescribing, and 
when, is required.</p>
<p ALIGN="LEFT">The GP should at all times be provided with a copy of the latest 
care plan. The</p>
<p ALIGN="LEFT">psychiatrist should continue to prescribe until shared care 
arrangements have been</p>
<p ALIGN="LEFT">agreed with the patient’s GP.</p>
<p ALIGN="LEFT">A guide to shared care protocols is attached at Appendix 2</p>
</font><font FACE="Arial"><b>
<p ALIGN="LEFT">Neuroleptic Malignant Syndrome</p>
</b></font><font FACE="Arial" SIZE="3">
<p ALIGN="LEFT">(Taken from The Maudsley Prescribing Guidelines 6</font><font FACE="Arial" SIZE="1">th
</font><font FACE="Arial" SIZE="3">edition, 2001)</p>
<p ALIGN="LEFT">There is an incidence of 0.5-1%, with a mortality of 20% if 
untreated. Onset may be</p>
<p ALIGN="LEFT">acute or insidious, and the course may fluctuate.</p>
</font><font FACE="Arial" SIZE="3"><b>
<p ALIGN="LEFT">Signs and symptoms are</p>
</b></font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Intense diaphoresis</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Fever/ hyperthermia</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Hypertension/ autonomic 
instability (fluctuating BP)</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Tachycardia</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Incontinence/ retention/ 
obstruction</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Muscular rigidity (may be 
confined to head and neck)</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Confusion/ agitation/ 
altered consciousness</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Raised creatinine 
phosphokinase &gt; 1000 IU/L (controversial)</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Leukocytosis</p>
</font><font FACE="Arial" SIZE="3"><b>
<p ALIGN="LEFT">Risk factors</p>
</b></font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Organic brain disease: 
alcoholism, dementia</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Hypermetabolic states: 
hyperthyroidism</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Psychiatric diagnosis</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Parkinson’s disease</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Agitation</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Dehydration</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">History of catatonia</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">High dose of antipsychotic</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Recent dose increase</p>
</font><font FACE="Arial" SIZE="3"><b>
<p ALIGN="LEFT">Precipitating factors</p>
</b></font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Antipsychotics: typical and 
atypical</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Rapidity of titration and 
dose of drug</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Antipsychotic withdrawal</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Antidepressants: including 
SSRI’s</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Abrupt cessation of 
dopamine agonists</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Other drugs: tetrabenazine</p>
</font><font FACE="SymbolMT" SIZE="3">
<p ALIGN="LEFT">• </font><font FACE="Arial" SIZE="3">Drugs of abuse: cocaine, 
MDMA, amphetamine</p>
</font><font FACE="Arial" SIZE="3"><b>
<p ALIGN="LEFT">Treatment</p>
</b>
<p ALIGN="LEFT">Withdraw antipsychotic immediately. Refer as a medical 
emergency.</p>
</font><font FACE="Arial" SIZE="3"><b>
<p ALIGN="LEFT">Complications</p>
</b>
<p ALIGN="LEFT">Renal, cardiovascular, respiratory and hepatic complications can 
occur.</p>
</font><font FACE="Arial" SIZE="2">
<p ALIGN="LEFT"></p>
</font>



<!-- Start of StatCounter Code -->
<script type="text/javascript" language="javascript">
var sc_project=585393; 
var sc_partition=4; 
var sc_security="8832a018"; 
var sc_invisible=1; 
</script>

<script type="text/javascript" language="javascript" src="http://www.statcounter.com/counter/counter.js"></script><noscript><a href="http://www.statcounter.com/" target="_blank"><img  src="http://c5.statcounter.com/counter.php?sc_project=585393&amp;java=0&amp;security=8832a018&amp;invisible=1" alt="php hit counter" border="0"></a> </noscript>
<!-- End of StatCounter Code -->



</body>

</html>
